47 results about "Therapy drug addiction" patented technology

Provided are analogs of methylphenidate (“MPH”) that are useful for the treatment of drug addiction, attention deficit disorder, attention deficit hyperactivity disorder, and depression. The MPH analogs are extended duration compounds that bind to the dopamine transporter and the reuptake of dopamine in the afflicted individual's brain. Because of the extended duration of the MPH analogs, administration of the compounds is only required on a once or twice daily schedule.

Patients susceptible to or suffering from disorders, such as central nervous system disorders, which are characterized by an alteration in normal neurotransmitter release, such as dopamine release (e.g., Parkinsonism, Parkinson's Disease, Tourette's Syndrome, attention deficient disorder, or schizophrenia), are treated by administering a compound of Formulas 1 or 2, as described herein. The compounds of Formulas 1 and 2 are also useful for treating pain, and treating drug addiction, nicotine addiction, and/or obesity. The compounds can exist as individual stereoisomers, racemic mixtures, diastereomers and the like.

The invention provides a compound of formula (I): wherein R1, R2, R3, and Y have any of the meanings defined in the specification; as well a pharmaceutical composition comprising a compound of formula I; intermediates and methods useful for preparing a compound of formula I; and therapeutic methods for treating drug addiction, Parkinson's disease or depression comprising administering a compound of formula I, to a mammal in need of such treatment.

The present invention is directed to a method for treatment of drug addiction and screening methods for identifying pharmaceutical agents that ameloriate or prevent the deleterious effects of addition. The invention is as well directed to a group of genes and a group of gene products that are up or down requested as a result of addiction.

The invention discloses novel application of imatinib and a derivative thereof and provides novel application of imatinib and the derivative thereof to preparation of drugs for preventing and/or treating drug addiction and preparation of drugs for preventing and/or treating relapse after drug withdrawal. According to the novel application, a classic rat sensitization and conditioned place preference animal model for evaluating addiction is adopted, the influences of imatinib and the derivative methanesulfonic acid imatinib on expression of the recrudescence behavior and sensitization behavior appearing after withdrawal of the conditioned place preference of a rat is formed are observed respectively, and the result indicates that imatinib and the derivative methanesulfonic acid imatinib have an inhibitory effect on morphine addiction and have the effect of preventing relapse after withdrawal of morphine addiction.

Compounds, compositions and methods for treating drug addiction, nicotine addiction, and/or obesity are disclosed. The compounds are N-aryl diazaspirocyclic compounds, bridged analogs of N-heteroaryl diazaspirocyclic compounds, or prodrugs or metabolites of these compounds. The aryl group can be a five- or six-membered heterocyclic ring (heteroaryl). The compounds are effective at inhibiting dopamine production and/or secretion, and accordingly are effective at inhibiting the physiological “reward” process that is associated with ingestion of nicotine and/or illicit drugs. The compounds and compositions can be administered in effective amounts to inhibit dopamine release, without resulting in appreciable adverse side effects (e.g., side effects such as significant increases in blood pressure and heart rate, significant negative effects upon the gastro-intestinal tract, and significant effects upon skeletal muscle).

The invention is directed to a method of treating addiction to drugs of abuse in a subject, comprising administering a therapeutically effective amount of a cabamoyl compound, or pharmaceutically acceptable salt or ester thereof.

The invention discloses new application of c-Kit, and provides application of the c-Kit serving as a drug target in screening of drugs for treating drug addiction and application of the c-Kit in screening of drugs for treating substance dependence addiction psychological craving and excitability of addiction drugs. A classical rat sensitization and conditioned place preference animal model for evaluating addiction is adopted for observing influences of an inhibitor imatinib of the c-Kit on renewed behaviors after formation and withdrawal of rat sensitization behavior expression and conditioned place preferences respectively, the inhibiting effect of imatinib on morphine addiction and an anti-relapse effect after withdrawal of morphine addiction is achieved are evaluated, and application of an acting target c-Kit receptor serving as the drug treatment target of drug addiction is determined. The c-Kit is good in effect and is expected to fundamentally treat drug addiction.

The invention relates to a deep brain stimulation electrode device which comprises a first electrode, a second electrode, a fixing sleeve and circuit connecting parts, wherein each of first electrodeand the second electrode comprises an electrode implantation part and an electrode fixing part; the electrode implantation part is used for being implanted into a specific target point of the brain; the electrode fixing part is fixedly arranged in the fixing sleeve, and the electrode fixing part and the fixing sleeve are insulated and isolated from each other; the fixing sleeve is arranged so as to be fixed to a position of a skull punching point; the first electrode and the second electrode are fixed to a preset position in the brain through the fixing sleeve; and the first electrode and thesecond electrode introduce electrical stimulation signals through the circuit connecting parts. Through the deep brain stimulation electrode device, electrical stimulation on the target point can be reliably and precisely realized through a dual-channel combined effect; the precise electrical stimulation on a predetermined brain area is achieved; the injury on the brain area is extremely little; the deep brain stimulation electrode device can be used for effectively and safely treating drug addiction; and the influence on free activities of a brain stimulation object by the structure is small.The deep brain stimulation electrode device has the advantages that the implementation of a manufacturing mode is simple; the cost is low; and the mass production is easily realized.

Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.

The present invention relates compounds of general formula (I) and stereoisomers and pharmaceutically acceptable salts and prodrugs thereof; wherein R' and R1 - R5 are as defined in the claims. The invention also relates to said compounds for use as a medicament and particularly in the treatment of drug addiction and CNS related diseases.

Disclosed are an extract that is effective in treating drug addiction and a preparation method therefor. An effective component of the extract has the following chemical structural characteristics: a cholestenol compound with hydroxyl (OH) at position 3 and a double bond between position 5 and position 6, or a cholestenol compound with hydroxyl (OH) at position 3, a double bond between position 5 and position 6 and a double bond between position 22 and position 23. The extract can be extracted from the traditional Chinese medicine Agriolima agrestis. The extract of the present invention is safe in acute toxicity, sedative and hypnotic without physical and psychic dependence, has an inhibitory effect on excitability in mouse caused by morphine and benzedrine and a detoxification treatment effect on the withdrawal symptoms in morphine-dependent rats, and is useful in the development of medications or food for treating drug addiction.

Methadone is a frequently employed agent for the treatment of drug addiction and the treatment of pain. Methadone prolongs the cardiac action potential, which on the surface electrocardiogram is represented by QT prolongation. This QT prolongation is known to increase the risk for the development of cardiac arrhythmias, especially the form of ventricular tachycardia known as Torsade de Pointes. For this reason, the FDA has inserted a “black box” warning for potential life threatening arrhythmias. The invention described in this application is the surprising finding that the R-isomer of methadone causes less inhibition of the potassium channel, IKr and thus would have less of a chance of causing life threatening arrhythmias. What is claimed is a method of chirally separating methadone with one isomer having less QT prolongation and more analgesic action that would make a superior pharmacologic agent than the racemate R,S methadone.

The present invention relates a method of treating drug addiction in an individual by administering to the addicted individual a therapeutically effective amount of dextro-morphine capable of activating an opioid receptor. It is disclosed here that dextro-morphine is suitable for treating addiction to natural opiates, semi-synthetic opiates, fully synthetic opioids, and endogenous opioid peptides, as well as nicotine.

The present invention relates to a selected amide of γ-hydroxybutyric acid, a process of manufacture and uses thereof. The invention also includes a pharmaceutical composition comprising an effective amount of the selected compound of the invention for use in preventing or treating drug addiction, especially alcohol misuse or dependency.

Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of drug addiction, more particularly, cocaine addiction. Passive immunization using antibodies raised against conjugates of the instant invention is also disclosed. The therapeutic composition is suitable for co-therapy with other conventional drugs.

The present invention relates to a pharmaceutical composition for treating drug addiction comprising herb Gelsemium elegans Benth. and the flower of herb Datura metel L., and optionally any pharmaceutically acceptable excipient, wherein the weight/weight ratio of the raw material of Gelsemium elegans Benth. to the raw material of the flower of Datura metel is from 2:1 to 6:1.